C4531001
The Pfizer Clinical Research Unit Brussels is conducting a study for the treatment of atopic dermatitis (AD).
Who may participate
This study is seeking healthy male and female participants, meaning that the participants will not have the condition being studied.
In addition to the criteria listed, participants must meet the following requirements:
- Have a minimum body weight of 50 kg
- Have body Mass Index of 17.5 - 32 kg/m2
- Be a non-smoker or a smoker who smokes a maximum of 5 cigarettes per day
- Be able to meet all study visit requirements
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
The study is planned to last for approximately 569 days. There are several examinations procedures required in connection with the study:
- A screening examination during which you will sign a COVID ICD and the study ICD
- 1 dosing period of 5* overnight stays at the PCRU. You will not be able to leave the PCRU during that time
- 11 planned follow-up visits
All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.